[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Exciting recent developments have proven the unique promise offered by Targeted Radionuclide Therapy (TRT) for better precision medicine.
Whether given alone or in combination, TRT and immunotherapy will have an important role to play in the treatment of cancer patients in the future.
Dr. Cyril Berthet will present the tools & expertise available today for the preclinical assessment of TRT.
Discover how to facilitate the translation of new targeted radionuclide therapies into clinical practice.
Find out about preclinical targeted radiopharmaceuticals projects, including combination studies with chemotherapies or immune checkpoint inhibitors!
Cyril Berthet is Pharmaco-imaging Unit Director & Director of Pharmimage Operations at Oncodesign.
He holds a PhD in Molecular and Cellular Biology from the University of Lyon, France. In 2002, he joined the Mouse Cancer Genetics Program at the National Cancer Institute in Frederick, US as a Research Associate. He joined Oncodesign in 2007 as a project leader and now manages strategic partnerships in therapeutic and biomarker discovery.